Background/Aims: Ulcerative colitis (UC) is a type of inflammatory bowel disease that mainly involves the colon. Thus far, glucocorticoids and amino-salicylate have been the main treatment. Methods: To assess drugs with fewer side effects, this study evaluated the effects of sodium cromoglycate (SCG) on acetic acid-induced UC in rats. The treatment groups included SCG receivers (50 and 100 mg/kg, intra-orally) and sulfasalazine (SSZ) receivers (100 mg/kg, intra-orally). The colonic mucosal injury was assessed by clinical, macroscopic, and histopathological examinations. Results: In the treatment groups with 50 and 100 mg/kg of SCG, the clinical activity score decreased to 2.67±0.18 and 1.73±0.21 (p<0.05), respectively, compared to the UC control group (3.21±0.31), and were higher than that of the group given the standard treatment of 100 mg/kg SSZ (1.10±0.09). The treatment groups with 50 and 100 mg/kg of SCG showed a lower clinical gross lesion score than the UC control group (2.91±0.28 and 2.10±0.43, vs. 4.49±0.61, p<0.05) and were higher than the standard group (0.95±0.18). Treatment with SCG (100 mg/kg) decreased the macroscopic scores significantly compared to the UC control group (p<0.05) on the 8th day. Conclusions: SCG (100mg/kg) decreased significantly the clinical activity score, gross lesion, and percentage-affected area compared to the UC controls on the 8th day. (Korean J Gastroenterol 2020;75:39-45) 
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic immunological disease of the gastrointestinal tract associated with austere ulceration, relapse bleeding, and diarrhea. IBD consists of two sub-families: Crohn's disease and ulcerative colitis (UC). Crohn's disease might involve all lining sites of the digestive tract, while UC is more specific to some parts of the gas-trointestinal tract, mainly the colon. 1 UC is generally a T-helper cell type 2-driven response that primarily affects the colonic mucosa and sub-mucosa. 2 The most common symptoms of UC are ulcers and inflammation of the inner lining of the colon that lead to bloody diarrhea, abdominal pain, urgency, and tenesmus. 3 Oxidative stress has been implicated in the pathogenesis of UC. The excess production of reactive oxygen species, such as superoxide, hydroxyl radical, hydrogen per-40 Zahra Ghafouri, et al. Sodium Cromoglycate and Ulcerative Colitis
The Korean Journal of Gastroenterology oxide, hypochlorous acid, and oxidant derivatives of N-chloramines, might be found in the inflamed mucosa of a UC case. 4 Intestinal mucosal immune cells, such as mast cells and eosinophils, are crucial in the pathogenesis of UC. 5 Chemically induced UC models are beneficial for studying the role of mast cells in the pathogenesis of the disease. Several chemical agents are employed to induce UC models, including trinitrobenzene sulfonic acid, dextran sodium sulfate, and acetic acid (AA). 6 Thus far, glucocorticoids and amino-salicylate have been used for UC treatment, 7 but their side effects remain a major clinical problem. 8 Sodium cromoglycate (SCG)
is an effective drug for the treatment of disorders associated with type I hypersensitivity reactions accompanied by mast cell degranulation and its importance in the management of asthma is accepted widely. 9, 10 As there is evidence of tissue eosinophilia and mast cell activity followed by increased histamine secretion in UC patients 11 and a lower incidence of side effects by cromolyn administration compared to glucocorticoids and aminosalicylate, 12 it was believed that SCG might be valuable in UC management. This study evaluated the impact of SCG on AA-induced UC through a com-parison of sulfasalazine (SSZ) treatment as a standard procedure.
SUBJECTS AND METHODS

Animals
All experimental procedures utilizing mice were performed in accordance with the National Institute of Health guidelines.
Male (220-250 g, n=48) Kunming mice were obtained from the Experimental Animal Center, Yasuj University of Medical Science (Yasuj, Iran). They were maintained in an animal house with a controlled constant temperature of 23±2°C, relative humidity of 55±5%, and a 12 hours light/dark cycle.
The animals were allowed access to tap water and standard laboratory chow ad libitum. The experiments were performed between 08:00 and 12:00 a.m. to avoid circadian influences.
Induction of UC
The animals were divided randomly into six groups consisting of eight members. Group I served as the normal control and received 1 mL saline intra-rectally after the administration of saline orally. Group II received 1 mL saline intra-rectally following the oral administration of SCG (100 mg/kg). Group III served as the UC control and received 1 mL AA intra-rectally following the oral administration of saline. Groups IV and V received 1 mL AA intra-rectally following the administration of SCG at 50 and 100 mg/kg doses, respectively. Group VI received 1 mL AA intra-rectally following the administration of SSZ (100 mg/kg, intra-orally). All of the oral treatments were given for 3 days using an oral gavage.
On the 4th day of the treatment, the animals were fasted overnight with access to water ad libitum. On the 5th day, formed in the remaining groups on the 20th day ( Fig. 1 ).
Evaluation of the disease
1) Clinical activity score
UC was quantified with a clinical score assessing weight loss, stool consistency, and bleeding of the colon. No weight loss was counted as 0 points, weight loss of 1-5% as 1 point, 5-10% as 2 points, 10-20% as 3 points, and 20% or more as 4 points. For the stool consistency, the stool was collected in a thick paper and observed; 0 points were given for well-formed pellets, 2 points for pasty and semi-formed stools that did not stick to the anus, and 4 points for liquid stools that did stick to the anus. Bleeding was scored 0 points for no blood in the hem occult, 2 points for a positive hem occult, and 4 points for gross bleeding. The scores were added and divided by 3, forming a total clinical score that ranged from 0.0 (healthy) to 4.0 (maximal activity of UC).
2) Gross lesion score
An independent observer, who was blinded to the treatment, evaluated the severity of UC. For each animal, the distal 
RESULTS
Clinical activity and gross lesion scores
In the AA-induced UC mice (group III), the clinical activity scores were significantly higher than those of the normal groups (I and II) (3.21±0.31 vs. 0.0±0.0, p<0.05) (Fig. 2) .
AA caused severe macroscopic edematous inflammation in the colon. In the treatment groups with 50 (group IV) and 
Histopathological studies
On the 8th day, the AA-induced UC control (group III)
showed massive necrotic destruction of epithelium, sub-mucosal edema, areas of hemorrhages, and inflammatory cellular infiltration (Fig. 3C) . The group IV treatment showed mini-mal damage to the mucosa with slight sub-mucosal edema and mild inflammatory cell infiltration (Fig. 3D ), while group V showed remarkable recovery of the colonic mucosa from the AA-induced UC damage (Fig. 3E ). On the 20th day, tissue repair in groups IV, V, and III was higher than the control group, but the difference was not significant (Table 1) .
DISCUSSION
UC-induced inflammation usually involves the colon or rectum, 14 causing an atypical T-helper cell type 2 and T-helper cell type 9 response, which is recognized by the main symptoms of abdominal pain, diarrhea, and weight loss. 15 Perioperative management of UC includes aminosalicylates (SSZ and mesalamine), glucocorticoid supplementation, purine analogues (6-mercaptopurine/azathioprine), cyclosporine, calcineurin inhibitors, methotrexate, and immunomodulator therapy with anti-tumor necrosis factor agents. 16 For decades, SSZ, which had been categorized under aminosalicylates, was used as the first-line medication for UC. SSZ is absorbed in the small intestine. After re-excreting in the bile, the drug is transferred to the colon, having its azo bond split by bacteria and producing sulfapyridine and 5-aminosalicylic acid.
Sulfapyridine, which is the main cause of side effects, is then absorbed. 17 The drug's side effects are frequent but mostly reversible because of the sulfapyridine concentrations and low acetylation of the drug, some of which include gastrointestinal intolerance, malaise, headache, arthralgia, drug fever, red blood cells disorders, reversible hypospermia, and in rare cases, neurotoxicity, hepatotoxicity, poly-arteritis, and pulmonary fibrosis. 18 In one case, SSZ-induced pancytopenia was detected due to bone marrow suppression. According to that report, the treatment with SSZ needed to be ceased, and an urgent alternative therapy was needed for the patient. 19 Many other studies were in agreement with the urgency of a substitute or concurrent treatment in conjunction with SSZ. 20 According to the data published by Shi et al. 21 combination therapy of SSZ and bifidobacteria for a UC treatment is more effective in inhibiting the inflammatory processes and regulating immune systems.
According to the literature regarding SCG, SCG administration is suitable for long-term UC management, as well as for improving the patients' sense of well-being, and the sigmoidoscopic and rectal biopsy results. 9, 22 The data show that SCG is an effective treatment for chronic or recurrent enterocolitis in patients with Hirschsprung's disease. This is because SCG is not absorbed intestinally and there are no systemic side effects in its application. 23 The equipotent effect of SCG on the pylorus ligation model provides strong evidence for the antiulcer activity of the drug. This was based on the significant increase in the mucin content and the decrease in the total protein and pepsin contents in rats treated with SCG. 24 In the present study, the clinical and macroscopic char- declaring the effectiveness of SCG in healing ulcers. 9 The SSZ-treated group in this study (group VI), showed a normal colonic structure. According to the results, the potency of SCG to reduce the gross lesion score was far more than its ability to reduce the clinical activity score, and this potency was accelerated at higher SCG doses (Fig. 2) . This evidence was correlated with the histopathological manifestations in all treatments in the study (Fig. 3 ).
UC is a chronic disease that takes a long time (perhaps many years) to develop, including the onset of its clinical manifestations and symptoms. 25, 26 In the UC model in this study, UC caused by AA developed in less than a month. Therefore, it is related more closely to the acute form of IBD or UC, which manifests symptoms similar to exacerbation or inflammation in UC-induced mice. [26] [27] [28] SCG is well known for its mast cell stabilizer properties; 29 it inhibits the release of 44 Zahra Ghafouri, et al. Sodium Cromoglycate and Ulcerative Colitis
The Korean Journal of Gastroenterology histamine, leukotrienes, and slow-reacting substance of anaphylaxis from mast cells by inhibiting degranulation after exposure to reactive antigens. 30, 31 According to the results and data from this study, SCG could produce a palliative and partial recovery effect in the treatment groups compared to the control group.
In conclusion, the present data suggest that the SCG treatment of mice with a dose-response procedure effectively prevents AA-induced UC in mice. This protective effect highlights the alternative role of SCG as the standard treatment of UC.
